Chapter 13 - the report Patricia Morris left behind
Dr. Patricia Morris had died eight years earlier.
Her daughter Elena remembered her as stubborn, meticulous, and incapable of throwing away paper.
That trait suddenly mattered.
Elena searched boxes stored in her basement.
Old conference programs.
Medical journals.
Retirement letters.
Then she found a sealed envelope.
PENNSYLVANIA CHILDHOOD IMMUNITY PROJECT — PERSONAL NOTES.
Elena called Detective Cole before opening it.
The documents were reviewed properly.
Patricia’s notes described serious concerns in 1997.
Samuel Vale and Aaron Voss had pushed beyond the approved observational design.
Patricia objected.
The ethics committee halted the work.
But Patricia believed some biological samples disappeared before destruction could be verified.
She wrote:
S. Vale insists material destroyed. Inventory discrepancy unresolved.
Another line:
Asterion Foundation representative pressing for private settlement.
The sponsor connection went back thirty years.
Patricia named the representative:
Dr. Jonathan Sloan.
Rebecca Sloan’s father.
Two medical families.
Vale.
Sloan.
Two generations.
The modern BrightPath project was not a spontaneous rogue experiment.
It appeared to be an attempt to revive a research question their parents had been forced to abandon.
Elena felt anger colder than shock.
Children were not unfinished business.
Yet someone had treated them that way.
Patricia’s final note concerned Participant N.H.
Nora Harper.
Nora exhibited unusual response. Must ensure family informed if future research proposed. No re-contact without independent review.
That explicit protection had been ignored.
Martin Vale and Rebecca Sloan had used Nora’s archived data to identify Lila without consent.
When confronted with the school security footage and Patricia’s notes, Rebecca Sloan finally agreed to an interview.
She admitted visiting the school.
“I believed we were evaluating recruitment infrastructure.”
“For a study involving children?”
“For a future study.”
“Did you know BrightPath had already begun treatment?”
Sloan hesitated.
“That was not what Martin represented.”
“Did you see Lila’s file?”
“I saw coded records.”
“You physically entered the school.”
“Yes.”
“Did you know Nora Harper was a former participant?”
“Yes.”
“Did you know her daughter had been selected?”
Sloan stopped.
“Yes.”
The room went silent.
“What did you believe was happening?”
“A preparatory observational cohort.”
“Were you aware compounds were being administered?”
“No.”
Investigators would have to determine whether that denial was true.
Emails complicated it.
One message from Sloan to Vale:
Legacy response should be reproduced only if exposure parameters align.
Dr. Morris read it.
“That sounds like active intervention.”
Sloan’s lawyer argued the email referred to laboratory modeling.
Maybe.
Maybe not.
Then a second email:
Do not repeat 1997 mistake with documentation.
That could mean better ethics.
Or better concealment.
Context would matter.
Police searched Sloan’s corporate office.
One locked cabinet contained a sealed packet.
BRIGHTPATH — EXECUTIVE RISK.
Inside was a draft report.
It warned:
Pediatric administration currently lacks full institutional authorization.
If exposed, characterize as independent investigator deviation.
Detective Cole stared.
The company had anticipated exactly the defense it was now using.
Blame Voss.
Blame Vale.
Distance Asterion.
The report was dated four months before Lila collapsed.
Someone inside Asterion knew authorization was missing.
Who signed the risk memo?
Not Sloan.
A corporate attorney:
Benjamin Cross.
Investigators now had another layer.
But Lila’s case remained the center.
Her recovery continued.
She returned to school full time.
On her first Monday back, she stood slowly from her desk.
Ms. Kincaid noticed instantly.
“You okay?”
Lila looked at her.
For a second the classroom seemed to hold its breath.
Then Lila smiled.
“For real this time.”
Ms. Kincaid smiled back.
“Good.”
Lila took three steps toward the pencil sharpener.
No collapse.
No pain.
She returned to her seat.
Small victories.
After school, Nora picked her up.
Not Caleb.
The court granted Nora temporary primary custody.
Caleb’s contact remained supervised.
Lila asked whether she had to see him.
Her advocate told her she could talk about her feelings.
No one forced immediate reconciliation.
That night she drew four people.
Herself.
Mommy.
Ms. Kincaid.
Dr. Morris.
Then she drew Daddy on another page.
Not erased.
Not forgotten.
Just separate.
Nora asked:
“Why is Daddy over there?”
Lila shrugged.
“He has things to fix.”
A seven-year-old had summarized the entire case better than most adults.
Then Detective Cole received the Asterion risk memo’s attachment list.
One attachment was missing.
Item 7:
SECOND-GENERATION SUCCESSION PLAN.
The word “succession” disturbed everyone.
This was not simply about reproducing an old study.
May you like
Someone had planned what came after.
👉 Asterion’s hidden risk file showed executives knew BrightPath lacked proper authorization, while a missing “second-generation succession plan” suggested Lila’s cohort was only the beginning.
